179 related articles for article (PubMed ID: 12378012)
21. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
Sweetenham JW; Johnson PW
J Clin Oncol; 1994 Dec; 12(12):2766. PubMed ID: 7989954
[No Abstract] [Full Text] [Related]
22. [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
Li HH; Wu XX; Wang QS; Zhao Y; Bo J; Wang SH; DA WM; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):298-300. PubMed ID: 16638201
[TBL] [Abstract][Full Text] [Related]
23. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
24. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma].
Zhang MZ; Zang WP; Song M; Geng L; Li X; Wang RL
Ai Zheng; 2008 Apr; 27(4):435-7. PubMed ID: 18423133
[TBL] [Abstract][Full Text] [Related]
27. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[TBL] [Abstract][Full Text] [Related]
28. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.
Soussain C; Souleau B; Gabarre J; Zouabi H; Sutton L; Boccaccio C; Albin N; Charlotte F; Merle-Béral H; Delort J; Binet JL; Leblond V
Leuk Lymphoma; 1999 May; 33(5-6):543-50. PubMed ID: 10342581
[TBL] [Abstract][Full Text] [Related]
29. Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group.
Muntañola A; Baumann T; Caballero AC; Sánchez-González B; Mercadal S; Escoda L; Soler A; Iserte L; Canet M; Villalobos MT; Magnano L; Sorigué M; García O; Salar A; López-Guillermo A; Sancho JM
Ann Hematol; 2020 Jul; 99(7):1627-1634. PubMed ID: 32451707
[TBL] [Abstract][Full Text] [Related]
30. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma].
Imataki O; Tamai Y; Kawakami K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1629-32. PubMed ID: 17940378
[TBL] [Abstract][Full Text] [Related]
33. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Romaguera JE; Hagemeister FB; McLaughlin P; Rodriguez MA; Bachier C; Preti H; Sarris AH; Weber D; Younes A; Cabanillas F
Leuk Lymphoma; 1998 Dec; 32(1-2):97-106. PubMed ID: 10037005
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
35. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
36. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
37. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
38. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
Fernández de Larrea C; Martínez C; Gaya A; López-Guillermo A; Rovira M; Fernández-Avilés F; Lozano M; Bosch F; Esteve J; Nomdedeu B; Montserrat E; Carreras E
Ann Oncol; 2010 Jun; 21(6):1211-1216. PubMed ID: 19889622
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
40. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
